This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Precision Autism Through Light

Autism is a serious developmental disorder that lasts a lifetime. JelikaLite believes that children on the spectrum can lead fulfilling and productive lives. That is why they are developing Cognilum, an innovative medical solution to permanently reduce a child's autism symptoms, enabling better integration into society and reducing lifetime costs. Cognilum will demystify autism - by opening a window into the child's brain waves, it will empower both parents and doctors to precisely deliver the needed treatments. JelikaLite is a development stage company whose product is not yet available to the general market.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$624,121.94 Raised

Reason to Invest

  • Federal recognition achieved. FDA granted JelikaLite a Breakthrough Device Designation for its Cognilum system for reduction of symptoms of autism in pediatric patients aged 2 to 6

  • The autism market is growing. There are already over 1 million children living with ASD in the U.S. and 13 million children living with ASD in the world. The rates continue to increase.  Costs of treatment in the US are projected to rise to over $450B by the year 2025. (Source)

  • There are very limited solutions. Current treatment is limited to therapy and medications. Unfortunately, therapy is expensive, does not work for all children, has to stop during quarantine, and is frequently unavailable due to lack of trained therapists. Medications have side effects and do not treat the underlying cause of the disease.  

  • Our product is unique. Cognilum is an FDA-regulated medical device that provides safe noninvasive brain stimulation. It is designed to be easily administered in the child’s home, with time flexibility, privacy, and no need for the physical presence of a therapist.  This product may become the “game-changer” for autism treatment, and may be the only practical solution for many families. 

  • The treatment is personalized. The AI platform takes into account the child’s medical history, physical condition, symptoms and improvement. This data is used to continuously improve the treatment personalization.

  • Treatment improves the quality of life. We expect the overall benefit of Cognilum to be a 1/3 permanent improvement of each child's autism symptoms, resulting in over $1 million in lifetime savings.

  • Experienced team. Our multi-disciplinary team has experience in autism clinical therapy, medical device engineering and commercialization, tPBM research, artificial intelligence, software product development, and finance. 

  • Effective Clinical Results. JelikaLite has completed the Phase I placebo-controlled clinical trial of its prototype and the results showed a statistically significant improvement in children who received the treatment. 


Precision Autism: Get more from life with light!

*Above graphic is a computer generated version.

Cognilum is a therapeutic wearable medical device which combines non-invasive brain stimulation using near-infrared light, EEG sensors and an AI personalization platform.

The non-invasive wearable device provides neurostimulation through transcranial photobiomodulation (tPBM). The device also measures brains’ electrophysiological activity through EEG.

The software platform monitors each child’s developmental trajectory, warns parents and doctors about any set-backs, and personalizes treatments.    

Cognilum will enable children to integrate into society; parents to receive a home-based easy-to use personalized cost-effective treatment — therapists to track progress and efficacy of existing interventions, and both payers and government to spend less money on special education and lifelong residential care - It will allow parents and children to have less stressful, more predictable and more fulfilling lives.


The benefit is expected to be a 1/3 permanent improvement of a child's autism symptoms, as demonstrated by gains in communication and daily living skills, resulting in over $1MM in savings over an individual's lifetime cost of autism.


There is no cure for Autism

1 out of 44 children in the US are now diagnosed with Autism (Source). The rates continue to rise, the cause of the disease remains unknown and there is no cure. 

The vast majority of affected individuals have difficulties with language learning and 40% remain non-verbal. (Source)


Costs of treatment in the US are projected to rise to over $450B by the year 2025. (Source) Individual’s lifetime costs range from $1.5MM to $3.5MM, depending on the severity of symptoms. (Source)

There are several unmet needs that all parents of children with autism  are grappling with: the pervasive symptoms, lack of consistently effective treatment, lack of treatment continuity, the effectiveness of various interventions is hard to measure quantitatively, busy parents have difficulty scheduling the needed therapy and following through with lessons at home.

Furthermore, autism rates among racial minorities in the US have increased by double digits in recent years. (Source) Exacerbating this rise are major racial and socio-economic disparities in access to Early Intervention services. Therefore, there is a significant unmet need for a convenient home-based personalized effective treatment that does not rely on the continued physical presence of a trained therapist and that provides data to the parent and therapist so they can quantitatively and consistently measure the effect of various interventions.


We use infrared light technology to treat autism symptoms

JelikaLite developed Cognilum, a wearable headset that harnesses the power of Photobiomodulation (PBM therapy) to reduce symptoms of autism in children, by improving language skills, and responsiveness. It is a data-integrated system that collects data from both the infrared headset as well as parental reports of a child’s observable behavior and symptoms which are analyzed on the platform. This platform provides personalized treatment for each child, including calculating expected developmental trajectory, tracking autism symptoms progressions, and optimizing various treatment interventions. 

*Above graphic is a computer generated version of the app.

PBM therapy is an innovative red / near infrared light treatment that is used to stimulate cellular functions. Simply, it increases cerebral blood flow and reduces inflammation, which helps the brain receive more oxygen and nutrition to heal. Cognilum can enable children to integrate into society and empower parents to receive a home-based cost-effective treatment while having a better quality of life.

JelikaLite will use a subscription-based model by collecting the revenue sources from the price of the therapeutic device and monthly access costs to the software platform. Initially, we expect the device to be paid for privately by parents, but with sufficient data, payers will be approached for reimbursement. The availability of insurance coverage is likely to increase the sales of the product significantly. 


Our innovative approach yields successful results

Regulatory: Received ‘non-significant risk device designation” from the FDA. 

Product:  developed a beta version of the physical prototype which was used in the Phase I clinical trial and developed initial assessments for the AI platform.

Awards: Won a FuzeHub Commercialization Competition.

Patents: Performed Freedom to Operate Search and filed 3 patents.  

Clinical:  In October 2021, JelikaLite finished a pivotal double-blind, placebo controlled clinical trial, using JelikaLite's proprietary prototype. The difference between the ‘active group’ and the ‘placebo group’ was statistically significant on each of the 3 separate measurements – Childhood Autism Rating Scale tests, parental reports of child’s progress and EEG data.

  • Children who received the treatment developed new verbal skills, improved socialization skills and responsiveness. 

The results of the clinical trial have been published and / or already accepted for publication and presentation in the following:  

·         Journal of the American Academy of Child & Adolescent Psychiatry, Volume 60 / Number 10S / October 2021

·         1st Annual Autism Conference  at Rutgers University Center for Autism Research, Education, and Services (10/28/2021):  

·         Brain Foundation, Synchrony 2021

Next steps:

  • Submitting a request for Break-through device designation to the FDA 
  • Working on Phase II clinical study protocol
  • Enhancing the prototype -  to be ready for Phase II trial and manufacturing


Parents are Seeking a Solution 

Mental and developmental disorders among children are on the rise. The causes of these diseases remains unknown and there are no known cures. There are existing tPBM products on the market, but none of them are designed for children or for autism treatment. There are existing software platforms, but none of them have the integrated feedback loop with the physical device nor AI personalization.

Cognilum is positioned to be unique: it is home based, easy to use for busy parents, provides a personalized feedback loop, and it is potentially expandable to other pediatric conditions. JelikaLite has several competitive advantages. First, we filed patents on the combination of tPBM, EEG sensors and personalization. Second, we already have access to a large number of organizations that work with children with autism and a community of parents. 

Most importantly, the data-device personalization feedback loop is unique for autism.  The platform will collect both physical measurements from the devices' sensors and behavioral data of children from parents and therapists, thus measuring the effectiveness of treatments and treatment interactions. This data can eventually establish correlations of condition severity and child’s progress with child’s demographic, medical and developmental history. Our AI protocol will analyze the disparate inputs, model the child’s developmental trajectory, and personalize treatment. 

As the platform collects more data from more parents, it will give us a constantly growing competitive advantage.


Real change for real children

We believe that all children on the autism spectrum can lead fulfilling and productive lives. Investing in our company gives investors both the opportunity to position themselves in a massive and growing market and an opportunity to improve the quality of life for millions of families across the world. 

JelikaLite will enable children to integrate into society, parents to receive a home-based cost-effective treatment while having a better quality of life, therapists to track progress and efficacy of existing interventions, and both insurance companies and government to spend less money on special education and lifelong residential care. 

Help us on our journey to become the face of hope in autism treatment and become a shareholder in JelikaLite.


30 Wall Street, 8th Floor
New York, NY 10005

Autism is a serious developmental disorder that lasts a lifetime. JelikaLite believes that children on the spectrum can lead fulfilling and productive lives. That is why they are developing Cognilum, an innovative medical solution to permanently reduce a child's autism symptoms, enabling better integration into society and reducing lifetime costs. Cognilum will demystify autism - by opening a window into the child's brain waves, it will empower both parents and doctors to precisely deliver the needed treatments. JelikaLite is a development stage company whose product is not yet available to the general market.


Eugenia Steingold
Eugenia Steingold
Co-Founder & Chief Science Officer

Dr. Eugenia Steingold is a NYS licensed psychologist with extensive experience in experimental research. Dr. Steingold received her PhD from Princeton University, specializing in psycholinguistics and cognitive psychology and she was a PostDoc in Harvard University, specializing in cognitive and linguistic development.

Katya Sverdlov
Katya Sverdlov
Co-Founder & CEO

Katya Sverdlov, CFA, Esq., received her BA in Economics from Cornell University and her JD degree from Brooklyn Law School. Ms. Sverdlov has over a decade of experience working in progressively senior positions in investment banking and portfolio risk management. Most recently, she was the founding attorney of a fast paced, boutique Trusts and Estates and Special Needs Law Firm in New York. 

Luis DeTaboada

Luis DeTaboada

Chief Technology Officer

Luis DeTaboada has several decades of experience bringing photobiomodulation medical devices to market. Most recently, he was a CTO of LiteCure, a company which, in late 2020, was successfully sold to DJO Global. Mr. De Taboada holds over one hundred patents, patent applications, and peer-reviewed publications in the field of tPBM therapy. He conducted preclinical and clinical studies. He designed and developed devices, developed protocols, and obtained regulatory approvals. He launched domestic and international sites and managed all technical aspects of multicenter, multinational clinical studies—including the first-in-man clinical studies of tPBM Therapy for neurological applications. 

Liza Logounova

Liza Logounova

Chief Operating Officer & Secretary

Liza Logounova has over a decade experience as a product manager in the environmental markets space, most recently holding a role of a Senior Technology Manager in Global Forest Watch department of the World Resources Institute (WRI). Liza helped build and bring to market various products within WRI, such as TerraMatch and Global Forest Watch Professional (GFW Pro). Prior to that Liza has been a director in the IHS Markit, where she played a lead role in Markit Environmental team’s full software product lifecycle for supporting international and national government and private initiatives to reduce water pollution, deforestation and carbon emissions. First half of her professional career she worked as a Vice President in the technology division of a major Investment Bank (Goldman Sachs). 

Maxim Kalachenkov

Maxim Kalachenkov


Maxim is a lawyer with decades of experience in multiple areas of law. He studied at The Institute of State and Law (ISL) of the Russian Academy of Sciences (RAS), the largest scientific legal center in the Russian Federation. Since 2000, Maxim has worked as the Head of the Legal Department at Mitro International Limited.

Ali Mostashari, PhD

Ali Mostashari, PhD


Member of World Economic Forum, is co-founder of LifeNome (, a precision health AI company. He is assisting JelikaLite in the development of the AI platform infrastructure.

Anne-Marie Maman

Anne-Marie Maman


Executive Director, Princeton Entrepreneurship Council at Princeton University. Founded 3 startup companies, each with innovative, leading-edge technology; licensed IP, led all aspects of the businesses, and negotiated acquisition of 1 company for nearly $10 million within 3 years of formation. She is advising JelikaLite in matters of fund-raising and corporate governance. 

Dr. Michael Hamblin, PhD

Dr. Michael Hamblin, PhD


Dr. Michael Hamblin PhD is an associate professor at Harvard Medical School and an Associate Chemist in Massachusetts General Hospital. He is a world leading specialist on photobiomodulation, with over 280 peer-reviewed publications, mostly on phototherapy. He is advising JelikaLite on existing studies on photobiomodulation and he is introducing JelikaLite to clinicians in the area.

Yuli Fradkin MD

Yuli Fradkin MD


Principal Investigator on the Phase I clinical trial. Associate Professor at Rutgers University, specialist in autism therapy and research.

Dr. Robert K. Naviaux, MD

Dr. Robert K. Naviaux, MD


Dr. Naviaux is a Professor of Genetics, in the Departments of Medicine, Pediatrics, and Pathology. He directs a core laboratory for metabolomics at UCSD. He is the co-founder and a former president of the Mitochondrial Medicine Society (MMS), and a founding associate editor of the journal Mitochondrion. He is an internationally known expert in human genetics, inborn errors of metabolism, metabolomics, and mitochondrial medicine. He is the discoverer of the cause of Alpers syndrome---the oldest Mendelian form of mitochondrial disease---and the developer of the first DNA test to diagnose it. Dr. Naviaux's lab has developed a number of advanced technologies like biocavity laser spectroscopy and mtDNA mutation detection by mass spectrometry.


Jan 19, 2022
$10k - $1.07M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*


Extremely Early Bird: First 7 days

15% Bonus Shares

Super Early Bird: Next 7 days

10% Bonus Shares

Early Bird: Next 3 days

5% Bonus Shares


Tier 1: $5000+

5% bonus shares

Tier 2: $10,000+

10% bonus shares

Tier 3: $20,000+

20% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

JelikaLite will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $.59 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $59. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Voting Rights of Securities Sold in this Offering

Each Investor shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Investor’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Investor, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Investor pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Investor is an individual, will survive the death, incompetency and disability of the Investor and, so long as the Investor is an entity, will survive the merger or reorganization of the Investor or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.


Article Image

NYS Manufacturing Now: Helping Children with Autism



Recent JelikaLite presentation on the results of the clinical trial and the underlying science

Dr. Eugenia Steingold presented in December 2021 at The BRAIN Foundation’s Synchrony 2021 Conference on translational autism. 

Dr. Steingold discussed transcranial photobiomodulation (tPBM) and the results of JelikaLite’s recent double-blind, placebo-controlled clinical trial, with children aged 2 – 6.

To learn more, please watch the full Presentation     


Campaign Closing Soon

We will be closing this campaign on 11:59 pm PST January 18, 2022. 


Jelikalite chosen as one of 6 companies to present at Princeton Women Founders Startup Showcase

We are delighted to announce that JelikaLite has been chosen as one of 6 companies to present at the second annual Princeton Women Founders Startup Showcase on January 27, 2022.


Exciting FDA news for Jelikalite

Today we are proud to announce that JelikaLite has been granted Breakthrough Device Designation from the FDA for our Cognilum System - an individualized, non-invasive, technology for the reduction of autism symptoms in pediatric patients.

This is a great milestone for JelikaLite and a strong vote of confidence in our company that has a potential to change the landscape in the current approach to Autism.   Congratulations to all JelikaLite team members, advisors, investors and supporters.   

We look forward to helping millions of children and their families experience a better future. 

You can read more in our Press Release 


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into JelikaLite.




a year ago

Hello, how long before i receive shares?



James Bondulich

a year ago

Hello Katya, as per your reply to Vilem's question below, is there any update as to when your company will be back with another offering at a higher valuation? As one of the many with a child on the spectrum, I hope your company can help us all, and I am happy to help your company along. Good luck in 2022.



J. W. Thomas


a year ago

Congrats to the team for developing a product much needed in our time. How does the Breakthrough Device designation impact future trials, if at all?



Kelly Moores

a year ago

Will you be working towards FDA approval for younger children only (those under 6), or is your intention to gain FDA approval for older children and adults as well?



Maria Gaite


a year ago

I invested 12/17/21, and the amount just got deducted from my bank. I googled Eugenia Steingold, and her LinkedIn showed she co-founded Calm Brain between March 2018 to March 2019. I want to know what happened to Calm Brain?



Vilem Fruhbauer


a year ago

Please why are you closing this campaign already on January 18th?



Yosef Hertz


a year ago

Why did the amount you raised go down from yesterday to today, from about $385k to about $261k today? Plz let me know



Ajith Potluri

a year ago

Hello Jelikalite team Great News, "Breakthrough Device Designation from the FDA for our Cognilum System - an individualized, non-invasive, technology for the reduction of autism symptoms in pediatric patients". It is the first steps towards great future for the company and for Autism Children's parents, they are desperate to find solutions to help their child. ABA therapy and other modalities of therapies can become more meaningful when your device available in the near future. I understand still long way to go and several studies need to be done to prove the efficacy to get the FDA aproval, it is a great beginning. Best wishes to the team



Vilem Fruhbauer


a year ago

Hello, I have some questions for you: 1) Why are you raising money now and why through crowdfunding? 2) How much more money will it take to have commercially available products, both the device and app? 3) How strongly do believe in the effectiveness and safety of your device in its current stage, and would you use it on yourself or family members for treatment even in case it would not be approved by FDA for sale to general public? 4) Are there any non-dilutive grants available, received, or applied for to help with funding this project? 5) How big is the total addressable market specifically for your device and app? 6) Considering the cost of such device and number of affected children - How much demand in terms of number of devices sold annually would be realistic to expect? I am not looking for any specific numbers, just a ballpark to find out if something like this is could be a $50M business to saturate the market or $5B business, etc... 7) How would you envision a successful exit event for investors in the current round should look like? I am not a fan of investing $500+ in projects without any sales, so the more straightforward and specific your answers are, the more likely I would consider to make an exception. Thank you, V.



Ajith Potluri

a year ago

Hello JelikaLite team I made investment within first 24 hours, got confirmation email, still nothing is showing up in my investment section , its been more than a week. Is there any feed back you have for me, Thank you




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.